Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.
Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.
Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.
Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has scheduled its first quarter fiscal year 2025 financial results announcement for May 7, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. Domestic callers can dial (800) 836-8184, while international participants should use (646) 357-8785. A live webcast will be accessible through the company's investor page and will remain archived for one year.
Sera Prognostics (Nasdaq: SERA) announced significant changes to its Board of Directors. Jeff Elliott, currently a senior advisor at Boston Consulting Group and board member of Quanterix , will join the board on March 20, 2025. Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, having previously served as CFO and COO at Exact Sciences.
The company also announced that Ryan Trimble will retire and step down as director on June 30, 2025, after 14 years of service. Additionally, Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders. Both departures are part of the board's ongoing efforts to refresh its composition and expertise.
These changes come at a important time as Sera begins leveraging its recent PRIME study results to build market presence for its PreTRM® test, focusing on improving maternal and neonatal health through pregnancy biomarker information.
Sera Prognostics (NASDAQ: SERA) announced its Q4 and full-year 2024 financial results, highlighting significant clinical achievements and financial developments. The company's PRIME study demonstrated promising results, showing a 25% reduction in neonatal morbidity and mortality index and an 18% reduction in neonatal hospital stay.
Financial highlights include: Q4 2024 revenue of $24,000 (down from $41,000 in Q4 2023), with operating expenses of $9.4 million (up 6% YoY). Full-year 2024 revenue was $77,000 (down from $306,000 in 2023), while net loss improved to $32.9 million (from $36.2 million in 2023).
The company successfully raised $57.5 million through a public offering in February 2025, extending its cash runway through 2028. As of December 31, 2024, Sera held $68.2 million in cash and equivalents. The funds will support US commercial expansion, European market preparation, and additional studies for their PreTRM test.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for March 19, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. Domestic callers can dial (800) 836-8184, while international participants should use (646) 357-8785. A live webcast will be accessible through the company's investor relations website and will remain archived for one year.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, from 9:50 a.m. to 10:20 a.m. ET.
President and CEO Zhenya Lindgardt will lead a fireside chat to provide company updates and discuss recent achievements. The company, which specializes in providing innovative pregnancy biomarker information to healthcare professionals and patients, will make the presentation available via live webcast. Interested parties can access both the live presentation and replay through the Investors section of Sera's website at www.seraprognostics.com.
Sera Prognostics (NASDAQ: SERA) has announced the pricing of a $50 million public offering, consisting of 1,250,000 shares of Class A common stock at $4.00 per share and pre-funded warrants to purchase 11,250,000 shares at $3.9999 per warrant. The company has granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares.
The offering, expected to close on February 12, 2025, is being managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. Sera plans to use the proceeds to expand commercial infrastructure in the United States, prepare for European Union expansion, fund studies for PreTRM test adoption, including a potential FDA submission, and for general corporate purposes.
Sera Prognostics (NASDAQ: SERA) has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase additional shares up to 15% of the total offering. Jefferies, TD Cowen, William Blair are acting as joint book-running managers, with RBC Capital Markets as a bookrunner.
The net proceeds will be used to:
- Expand commercial infrastructure in the United States
- Accelerate European Union expansion preparations
- Fund studies to increase PreTRM test adoption
- Potential FDA submission for broad PreTRM test approval
- General corporate purposes
The offering is subject to market conditions, with no guarantee of completion or final terms. A shelf registration statement on Form S-3 was previously filed and declared effective by the SEC.
Sera Prognostics (NASDAQ: SERA) has announced plans to host a virtual R&D Day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. The event will feature presentations from the company's management team and Dr. Brian Iriye, the principal investigator of the pivotal PRIME study from the High-Risk Pregnancy Center in Las Vegas.
The event will showcase results from the PRIME study (Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs) and include a Q&A session. Participants can join via conference call using US domestic number (800) 836-8184 or international number (646) 357-8785, or through the webcast link available on Sera's website. The webcast recording will be archived on the Investors page for one year.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. President and CEO Zhenya Lindgardt will deliver a presentation on January 16 at 9:45 a.m. PT, providing company updates and discussing recent achievements.
The company, which specializes in providing innovative pregnancy biomarker information to healthcare professionals and patients to enhance maternal and neonatal health, will make the presentation available via live webcast. Interested parties can access both the live presentation and its replay through the Investors section of Sera's website at www.seraprognostics.com.
Sera Prognostics (NASDAQ: SERA) announced that its PRIME study results will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025. Dr. Brian Iriye, principal investigator, will deliver the presentation focusing on how the PreTRM test, which identifies women at higher risk of preterm delivery, combined with targeted clinical interventions affects neonatal outcomes.
The study's enrollment was stopped in December 2023 after achieving at least one primary endpoint with statistical significance. The PRIME abstract was selected as one of five late-breaking presentations and is expected to be published in mid-January 2025. The annual Pregnancy Meeting™ is considered the world's leading conference on pregnancy, featuring various educational and scientific programs.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
